FTC approves Amneal’s $1.45bn acquisition of Impax
11-07-2018
FTC antitrust charges against Impax dismissed
25-05-2018
Impax to divest 10 products amid acquisition by Amneal
30-04-2018
Purdue Pharma sues Amneal over OxyContin
03-03-2017
19-10-2017
Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Amneal, Impax, generics, M&A, Chirag Patel, Paul Bisaro